OMERS, Goldman Sachs, AXA IM completed the acquisition of amedes from Antin for $1.75bn.

OMERS, an infrastructure investment company, Goldman Sachs Asset Management and AXA IM, an alternative investments provider, completed the acquisition of amedes, a provider of medical diagnostics services from Antin, for $1.75bn. “We are pleased to continue the extremely positive development of our specialist network with a new owner group that appreciates our medical performance and supports our growth potential in specialized diagnostics and therapy. The consortium would like to have a long-term commitment to amedes, share our strategic goals and rely on continuity in the course we have chosen . We are very grateful to Antin for the trust they have placed in amedes throughout their investment cycle. Together with Antin, we have achieved important strategic goals and expanded our position as a leading company for integrated special diagnostics and therapy," Wolf Frederic Kupatt, amedes CEO.